Minireviews
Copyright ©The Author(s) 2021.
World J Methodol. May 20, 2021; 11(3): 61-74
Published online May 20, 2021. doi: 10.5662/wjm.v11.i3.61
Table 1 Selected series of stereotactic irradiation for low grade glioma including pediatric patients
Ref.
Study period
Number of patients
Proportion of pediatric patients (%)
Histology
Setting
Treatment
Dose (Gy)
Age (yr)
Tumor size
Prior irradiation
Follow-up duration
Tumor control or PFS (%)
Barcia et al[73], 19941978-19911650LGGPrimary or boost therapySRS by use of a cobalt source and stereoguideMean margin dose 21.7 GyMedian age 20 yr (range: 4-68 yr)-12 patientsMedian 50 moTumor control 81
Somaza et al[74], 19961990-19939100Pilocytic astrocytomaAdjuvant or salvage therapyGKSRSMedian margin dose 15 GyMean age 8.6 yr (range: 4-17 yr)Mean tumor diameter 16 mm 2 patientsMedian 19 moTumor control 100
Kida et al[75], 2000200012 (total number of patients in the study is 51)100WHO Grade I low grade astrocytomaAs part of initial management or salvage therapyGKSRSMean margin dose 12.5 GyMean age 9.8 yrMean tumor diameter 25.4 mm-Mean 27.6 moTumor control 91.7
Boëthius et al[76], 20021978-19971984.2Pilocytic astrocytomaAdjuvant therapyGKSRSMedian margin dose 10 GyMean age 10.6 yr (range: 2-60 yr)Median 2.2 cc2 patientsMedian radiological follow-up 4.7 yrTumor control 94.7
Hadjipanayis et al[77], 20031987-20004959Pilocytic astrocytoma (37 patients) and WHO Grade II fibrillary astrocytoma (12 patients)As part of initial management or salvage therapyGKSRSMedian margin dose 15 GyMedian age 14 yr (range: 3-52 yr) for patients with pilocytic astrocytoma and median age 25 yr (range: 5-57 yr) for patients with WHO Grade II fibrillary astrocytomaMedian 3.3 cc13 patientsMedian 32 mo after SRSTumor control 67
Saran et al[78], 20021994-199914100LGGAs part of initial management or salvage therapyLINAC-based SRTTotal dose 50-55 GyMedian age 8 yr (range: 5-16 yr)Median 19.5 cc0 patientMedian 33 moPFS 87 at 3 yr
Marcus et al[79], 20051992-199850-WHO Grade I-II astrocytomaSalvage therapyLINAC-based SRTMean total dose 52.2 GyMedian age 9 yr (range: 2-26 yr)≤ 5 cm in maximal dimension in all patients0 patientMedian 6.9 yrPFS 82.5 at 5 yr, PFS 65 at 8 yr
Wang et al[80], 20061993-200321-LGGPrimary, boost, adjuvant or salvage therapyGKSRSMedian margin dose 14.5 GyMedian age 20 yr (range: 6-70 yr)Median 2.4 cc7 patientsMedian radiological follow-up 49 moTumor control 67
Kano et al[81], 20091987-200650100Pilocytic astrocytomaAs part of initial management or salvage therapyGKSRSMedian margin dose 14.5 GyMedian age 10.5 yr (range: 4.2-17.9 yr)Median 2.1 cc5 patientsMedian 55.5 moPFS 70.8 at 5 yr
Henderson et al[82], 20091997-200412-WHO Grade I LGG (10 patients), WHO Grade II LGG (2 patients)As part of initial management or salvage therapyGKSRSMedian margin dose 13 GyMedian age 17.4 yr (range: 5.9-63 yr)Median 4.4 cc4 patientsMedian 48.2 moPFS 75 at 4 yr
Weintraub et al[83], 20121989-201124100LGGAs part of initial management or salvage therapyGKSRSMedian margin dose 15 GyMedian age 11 yr (range: 4-18 yr)Mean 2.4 cc3 patientsMedian imaging follow-up 74 moTumor control 83
Hallemeier et al[84], 20121992-20051833Pilocytic astrocytomaAs part of initial management or salvage therapyGKSRSMedian margin dose 15 GyMedian age 23 yr (range: 4-56 yr)Median 9.1 cc10 patientsMedian 8 yrPFS 41 at 5 yr
Lizarraga et al[85], 20121995-20101241.7Pilocytic astrocytomaSalvage therapyLINAC-based SRS or SRTMedian dose 18.75 Gy for SRS and median dose 50.4 Gy for SRTMedian age 21 yr (range: 5-41 yr)Median 6.5 cc for SRT and median 1.69 cc for SRS0 patientMedian 37.5 moPFS 73.3 at long term
Simonova et al[86], 20161992-200225100Pilocytic astrocytomaAs part of initial management or salvage therapyGK-based SRS or SRTMedian margin dose 16 Gy for patients receiving single fraction, median dose 25 Gy for SRTMedian age 13 yr (range: 3-17 yr)Median 2.7 cc2 patientsMedian 15 yrPFS 80 at 10 yr
Trifiletti et al[87], 20171990-201528-Pilocytic astrocytomaAs part of initial management or salvage therapyGK-based SRS or SRTMedian margin dose 16 GyMedian age 17.4 yr (range: 2-70.3 yr)Median 1.84 cc4 patientsMedian 5.4 yrPFS 96 at 6 yr
Gagliardi et al[88], 20172001-20143923.8LGGAs part of initial management or salvage therapyGKSRSMedian margin dose 15 GyMedian age 31 yr (range: 9-72 yr)Median 1.24 cc8 patientsMedian 54.5 moPFS 52.8 at 5 yr